MedPath

Evaluating the Usability of the Product Kinder System Trial, Home Based Hormone for In-Vitro Fertilization (IVF) Monitoring System.

Recruiting
Conditions
Fertility Disorders
Registration Number
NCT05634850
Lead Sponsor
Planet Innovation
Brief Summary

In-vitro fertilisation (IVF) treatment involves women undergoing hormone stimulation (drug dosing) to produce more oocytes (eggs) to increase their chances of fertilisation. The information that IVF clinicians currently collect on a woman's hormonal response to IVF drug dosing comes from in-clinic blood testing. This requires patients to make a visit to the IVF clinic every few days to have the blood samples taken. The blood is then analysed in a laboratory for the hormone levels and the results are then sent back to the clinic. This monitoring process of frequent onsite visits and blood draws can often be quite inconvenient and disruptive for patients.

This observational study will assess a non-invasive in vitro diagnostic (IVD) device for measuring the common fertility hormones in urine. The test system is for use by both healthcare professionals in a clinical setting and nonprofessionals in a home care setting under the guidance of a health care professional. This study will provide pilot data on the usability of the IVD device from the intended end users as well as the correlation of urinary metabolite levels as measured by the IVD device and the serum concentration as measured by blood analysers.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
25
Inclusion Criteria
  • Women undergoing controlled ovarian stimulation treatment
  • 30 to 40 years old (inclusive)
  • Willingness to comply with study procedures for collection and testing of urine
Exclusion Criteria
  • Illiterate in English
  • No access to smart phone that is compatible with App and/or is not connected to the internet
  • Patients who are diabetic (Type I and Type II), have insulin resistance or a renal/liver disorder
  • Patients who have taken oral contraceptives up to 4 days before the first stimulation day of the cycle

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the usability of Kinder by patients undergoing controlled ovarian stimulation cycleA single controlled ovarian stimulation cycle, typically up to 20 days

Patients will perform tests with the Kinder system and complete a usability questionnaire on their experience.

Correlation of fertility hormone serum and urinary metabolitesA single controlled ovarian stimulation cycle, typically up to 20 days

Correlation of E2, P4 and LH and their urinary metabolites (E1-3G, PdG and LH)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

National University Hospital

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath